| INTRODUC TI ON
Multiple myeloma is a disease characterized by the proliferation of differentiated plasma cells leading to hematopoietic tumors. The incidence of MM in the USA is 6.6 cases per 100 000 people, with a lifetime risk of developing MM of 0.8%. 1 In Japan, the incidence is slightly lower, at 5.5 per 100 000, but this has increased dramatically since 1975 when the incidence per 100 000 people was 0.9. 2 Several combination regimens including melphalan, prednisolone, and bortezomib base combination, lenalidomide base combination, and intensive chemotherapy with hematopoietic stem cell transplantation have been evaluated as first-line treatments, and the outcome for MM patients has improved. 3 Although these treatment options have improved OS markedly in MM patients, 3 MM usually relapses and remains incurable in most cases.
Carfilzomib is a second-generation epoxyketone protease inhibitor that irreversibly inhibits the chymotrypsin-like activity of the proteasome. 4, 5 In a phase 2 study (PX-171-003-A1) of patients with RRMM, carfilzomib monotherapy of 20-27 mg/m 2 showed an ORR of 23.7%, a PFS of 3.7 months, and an OS of 15.6 months. 6 Notably, carfilzomib expressed efficacy for bortezomib-resistant patients and was not associated with PN. Consequently, the United States Food and Drug Administration approved carfilzomib monotherapy through the accelerated approval process based on this phase 2 study. Phase 3 studies such as ASPIRE 7 (evaluating carfilzomib, lenalidomide, and dexamethasone) and ENDEAVOR 8 (evaluating carfilzomib and dexamethasone) showed clinically meaningful efficacy and safety profiles for the treatment of RRMM. Based on these phase 3 results, carfilzomib was approved worldwide for the treatment of RRMM. Moreover, recent long-term analyses of the ASPIRE 9 and ENDEAVOR 10 studies expressed significant and clinically meaningful OS improvement versus standard therapies. To our knowledge, carfilzomib is the first and only MM treatment that extends OS in the relapsed setting over the current standard of care. Since 2010, carfilzomib has been studied in Japan as monotherapy, as two-drug combination with dexamethasone, and as three-drug combination with lenalidomide and dexamethasone, and these studies yielded promising results for Japanese RRMM patients. [11] [12] [13] In an interim analysis of this study, 13 we reported the short follow-up period data of singleagent carfilzomib in Japanese patients with RRMM. Here, we present the final results of the study with long-term follow-up data.
| MATERIAL S AND ME THODS

| Ethics
The study was conducted in accordance with the principles of 
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| Overall study design
The study design has been previously reported in detail. 13 
| Study patients
Full inclusion and exclusion criteria have previously been published. 13 Patients were inpatients aged ≥20 years with symptomatic with G-CSF product (G-CSF products were prohibited during DLT evaluation), febrile neutropenia (neutrophil count <1000/mm 3 and fever >38.3°C), and grade 4 thrombocytopenia requiring platelet transfusion or accompanied by bleeding.
| Treatments
When three patients enrolled in the same cohort completed evaluation for the 28-day period (1 cycle) and no study drug-related DLT occurred, the next dose-level cohort was initiated. If a study drug-related DLT occurred in one of three patients, three more patients were to be enrolled in the same cohort. If a study drug-related DLT occurred in two or more of the three patients (or three or more of the six patients after patients have been added), enrollment in the same cohort was suspended, and the dose was regarded as the maximum dose. If the dose in cohort 2 or subsequent cohorts was the maximum dose, the dose from the previous cohort was defined as the MTD. The MTD was used in phase 2.
In cases where the dose could be increased to cohort 3 and the number of patients with DLT in cohort 3 was ≤2 of six patients, the dose for cohort 3 was planned to be the dose for phase 2. The final decision on the dose for phase 2 was made through deliberation by the sponsor and coordinating investigator. The opinion of the Efficacy and Safety Monitoring Committee was sought as necessary.
| Efficacy assessment
Efficacy was analyzed in the full analysis set, comprising patients who received at least one dose of the study drug and underwent at least one efficacy or pharmacodynamics evaluation after receiving the study drug. The primary endpoint of the study was the ORR (defined as sCR + CR + VGPR + PR). Response was evaluated based on central laboratory data according to the International Myeloma Working Group uniform response criteria. 14 The minimal response was evaluated using the European Group for Blood and Marrow Transplantation criteria. 15 Other endpoints were PFS, OS, and DOR.
Subgroup analysis of PFS was carried out to identify factors that influence efficacy.
| Safety assessment
Safety was evaluated in the safety analysis set, comprising all patients who had received at least one dose of the study drug. AE were graded according to the National Cancer Institute Common
Terminology Criteria for Adverse Events version 4.0.
| Statistical analyses
Statistical analysis was carried out by Ono Pharmaceutical Co., Ltd.
The ORR, primary endpoint for phase 2, was calculated for evaluable patients whose best responses were classified as sCR, CR, VGPR, or PR and the corresponding two-sided 95% CI was calculated using the Wilson method. Median OS and PFS were calculated using the Kaplan-Meier method. No significance level was specified, and no statistical tests were carried out for safety and efficacy measures.
Data were analyzed using SAS version 9.3 or later (SAS Institute Inc.).
| RE SULTS
| Baseline demographic and clinical characteristics
In the present study, the patients' last visit was on May 12, 2017, and the median follow-up period of this final analysis was 21.7 months.
The data cutoff date of the interim analysis was June 11, 2014, and the median follow-up period was 6.3 months. The baseline demographic and clinical characteristics were previously reported.
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Briefly, 50 RRMM patients who had received a median of five (range:
3-10) previous treatments were enrolled in this study between August 2011 and January 2014. Fifteen (30%) patients had high-risk cytogenetics, that is, were positive for del(17p) in ≥20% of screened plasma cells, t(4;14), t(14;16), or hypodiploidy.
| Dose escalation
Description of the dose escalation was previously reported. 
| Overall response rate and clinical benefit rate
The efficacy analysis set comprised all 50 patients enrolled in this study. ORR in the 20/27 mg/m 2 group was 22.5% (9/40) (95% CI, 12.3-37.5) ( Table 1) . One patient (2.5%) achieved sCR and two patients (5.0%) achieved VGPR. CBR was 32.5% (n = 13) (95% CI, 20.1-48.0).
| Progression-free survival, overall survival, and duration of response
Median PFS and the OS in the 20/27 mg/m 2 group were 5.1 months (95% CI, 2.8-13.6) and 22.9 months (95% CI, 14.1-not estimable), respectively, at the final analysis. Kaplan-Meier estimates of PFS are shown in Figure 1 and OS in Figure 2 . Median DOR was
months (95% CI, 2.3-not estimable). Subgroup analysis of PFS
in the 20/27 mg/m 2 group is shown in Table 2 .
| Safety
Fifty patients who received at least one dose of carfilzomib were included in the safety analysis set. All 50 enrolled patients experi- 
| D ISCUSS I ON
Results of the present study show the long-term benefit of carfilzomib 20/27 mg/m 2 monotherapy in patients with RRMM. ORR (the primary endpoint for phase 2) in the carfilzomib 20/27 mg/ m 2 group was 22.5% (95% CI, 12.3-37.5) at the final analysis. This ORR was the same result as in the interim analysis of this study.
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One patient (2.5%) achieved sCR, four (10.0%) achieved a minimal response. The CBR increased from 27.5% at the interim analysis to 32.5% after long-term exposure to carfilzomib 20/27 mg/m 2 . The median PFS with carfilzomib 20/27 mg/m 2 was 5.1 months (95% CI, 2.8-13.6), and the median OS was 22.9 months (95% CI, 14.1-not estimable). According to the subgroup analysis of PFS, prior bortezomib exposure seemed to influence the PFS results. This trend was similar to that reported in the PX-171-003-A1 study. 6 Although carfilzomib is an active drug for patients who are refractory to previous bortezomib, the exposure to bortezomib may slightly impact the response.
F I G U R E 1 Progression-free survival of patients treated with carfilzomib monotherapy
In 13 patients whose most recent treatment included bortezomib, the median PFS was 3.9 months. A favorable efficacy profile of carfilzomib monotherapy was observed.
Importantly, no new safety concerns were raised during the longterm follow up compared with the interim analysis. Carfilzomib monotherapy has previously been evaluated in MM patients in a phase 2 study (PX-171-003-A1) 6 and in a randomized phase 3 study (FOCUS). 16 In the PX-171-003-A1 study, 6 ORR was 23.7%, median PFS was 3.7 months, and median OS was 15.6 months. In the FOCUS study, ORR was 19.1%, median PFS was 3.7 months, and median OS was 10.2 months. The current efficacy results are consistent with these previous study data. Median duration of treatment was 3.0 (range, 0.03-16.9) months in the PX-171-003-A1 study 6 and 3.8 (range, 0.07-31.9) months in the FOCUS study. 16 In the present study, treatment with carfilzomib was more prolonged (4.7 months [range, 0.3-39.4]) than in these previous studies. 6, 16 We presume that the investigators' adequate management of the emerging AE during carfilzomib treatment contributed to the long-term administration of carfilzomib, which, in turn, led to good efficacy. Regarding carfilzomib safety, the incidences of most of the AEs were similar to those reported in previous studies;
however, the incidences of laboratory abnormalities, such as abnormal blood cell count and increased serum creatinine, seemed higher than in previous studies. 6, 16 We have noticed that in Japanese studies, laboratory abnormalities tend to be reported more frequently than in studies conducted elsewhere; we presume this may be because Japanese physicians tend to report laboratory abnormalities very carefully. In particular, on the day after giving carfilzomib, creatinine levels tended to transiently increase, but then returned to baseline levels by the time of the next dose. Therefore, during carfilzomib monotherapy (without dexamethasone), administration of the drug may be related to an acute and transient increase in creatinine. Moreover, acute kidney injury was reported as the most common adverse event leading to carfilzomib discontinuation (1.7%) when carfilzomib 20/27 mg/m 2 was given with dexamethasone in the phase 3 A.R.R.O.W. study.
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Additionally, in the present study, weight gain, edema, and peripheral edema were observed in 7.5%, 2.5%, and 5% of patients, respectively, in the carfilzomib 20/27 mg/m 2 group. Peripheral edema also occurred in 25.0% of patients in the 15 mg group. No grade ≥3 weight gain, edema, or peripheral edema occurred. As with the increase in creatinine, we consider that weight gain and edema were mainly attributable to acute dose effects.
F I G U R E 2 Overall survival of patients treated with carfilzomib monotherapy
A previous phase 3 study of pomalidomide and low-dose dexamethasone included a similar population (median of five prior treatments) to the current study. In that study, ORR was 31%, median PFS was 4.0 months, and median OS was 12.7 months, 18 which are similar to the results of the present study.
Although the results of the present study need to be interpreted in light of the relatively small number of patients, the inclusion of only Japanese patients, and the lack of a comparator group, this study confirmed that long-term (>3 years) monotherapy with carfilzomib (20/27 mg/m 2 ) is feasible in Japanese patients with heavily pretreated RRMM. Thus, we consider that carfilzomib monotherapy could be an effective maintenance therapy for RRMM, even for patients who have previously received intensive therapy with the triplet regimen (carfilzomib 20/27 mg/m 2 , lenalidomide, and dexamethasone) 9 or the high-dose regimen (carfilzomib 20/56 mg/m 2 and dexamethasone). 10 Further studies are required to address the above limitations.
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